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In 2005, 880 West Nile virus cases were reported in 
California; 305 case-patients exhibited neuroinvasive dis-
ease, including meningitis, encephalitis, or acute ﬂ  accid 
paralysis. Risk factors independently associated with de-
veloping neuroinvasive disease rather than West Nile fever 
included older age, male sex, hypertension, and diabetes 
mellitus.
S
ince the ﬁ  rst identiﬁ  cation of West Nile virus (WNV) in 
North America in New York, New York, in 1999, the 
virus has spread rapidly westward across the United States. 
In 2004 and 2005, California was the national epicenter of 
WNV activity, with 779 and 880 cases, respectively. The 
aim of this study was to identify potential risk factors for 
developing West Nile neuroinvasive disease among the 
WNV case-patients reported in California.
The Study
WNV human surveillance in California is conducted 
through several different mechanisms. Local clinicians 
are asked to refer patients with evidence of WNV disease, 
including encephalitis, aseptic meningitis, acute ﬂ  accid 
paralysis, or illness compatible with West Nile fever, for 
testing which is performed by 33 local public health labo-
ratories and the state Viral and Rickettsial Disease Labora-
tory (VRDL). Persons with suspected cases are also tested 
through the California Encephalitis Project (1), which pro-
vides enhanced diagnostic testing for several viral agents 
that cause encephalitis, including WNV. In addition, Kai-
ser Permanente laboratories screen patients with suspected 
cases and forward positive specimens to VRDL for further 
testing, while commercial reference laboratories forward 
positive test results. Blood collection centers forward re-
ports of WNV-positive donors, and local health depart-
ments perform follow-up investigations to identify donors 
in whom clinical disease later develops.
Local health departments use a standardized case his-
tory form to collect demographic and clinical information 
about patients who meet the clinical and laboratory criteria 
for WNV infection. Patients are classiﬁ  ed as having West 
Nile fever if they exhibit symptoms of WNV infection (e.g., 
fever, headache, or muscle weakness) without development 
of neurologic manifestations (e.g., encephalitis, meningitis, 
or acute ﬂ  accid paralysis). The case history form includes 
questions about hypertension and diabetes.
The 880 case-patients identiﬁ  ed were reported from 
40 of 58 counties in California, with illness onset ranging 
from May through November 2005. The median age of all 
case-patients was 50 years (range 2–95 years), compared 
to a median of 78 years for the 19 WNV patients who died 
(range 56–92 years; p<0.0001); 55% of all patients were 
male. Of the 880 cases, 534 cases were classiﬁ  ed as West 
Nile fever and 305 as WNV neuroinvasive disease. Not sur-
prisingly, a greater proportion of the patients with neuroin-
vasive disease were hospitalized (90%) and required inten-
sive care (27%) compared with the West Nile fever patients 
(31% and 2%, respectively; p<0.0001). The neuroinvasive 
disease patients also reported a greater frequency of severe 
symptoms such as altered mental status (54%) and seizures 
(7%) than did the West Nile fever patients (15% and 0.7%; 
p<0.0001 and p<0.001, respectively). Rash was reported 
among 22% of neuroinvasive disease patients compared 
with 51% of West Nile fever patients (p<0.0001), possi-
bly because those with more severe disease are less able to 
mount an inﬂ  ammatory response (2) (Table 1).
A greater proportion of neuroinvasive disease patients 
(46%) reported hypertension as an underlying medical con-
dition than did the West Nile fever patients (29%; p<0.001). 
Thirty-three percent of the neuroinvasive disease patients 
reported having diabetes mellitus, compared with 11% of 
the West Nile fever patients (p<0.001).
In response to an open-ended question about past med-
ical history, 193 (22%) of all case-patients reported other 
underlying illnesses. Coronary vascular disease was the 
most common underlying condition in both neuroinvasive 
disease and West Nile fever patients (23% and 17%, respec-
tively). Other medical conditions reported for patients with 
neuroinvasive disease included renal insufﬁ  ciency (10%) 
and chronic obstructive pulmonary disorder (8%); cancer 
(10%) and asthma (9%) were more frequently reported for 
West Nile fever patients.
Using SAS version 9.1 software (SAS Institute, Inc., 
Cary, NC, USA), we conducted a univariate analysis to 
compare the characteristics of patients with neuroinvasive 
disease to those with West Nile fever (Table 2). Odds ratios 
(ORs) and 95% conﬁ  dence intervals (CIs) were calculated 
by using Cochran-Mantel-Haenszel statistics. Patients with 
neuroinvasive disease were twice as likely to have hyper-
tension (95% CI 1.44–3.01) and 4 times more likely to have 
diabetes (95% CI 2.63–6.55) than West Nile fever patients. 
Other risk factors for neuroinvasive disease included age 
1918  Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 13, No. 12, December 2007
*California Department of Public Health, Richmond, California, 
USAWest Nile Virus Neuroinvasive Disease
>64 years (OR = 2.24, 95% CI 1.62–3.11) and male sex 
(OR = 1.57, 95% CI 1.18–2.09). Because of its collinearity 
with diabetes, hypertension was dropped from the logis-
tic regression model. Age >64 years (p = 0.03), male sex 
(p<0.01), and diabetes (p<0.0001) were independently as-
sociated with neuroinvasive disease.
Conclusions
To our knowledge, this report summarizes the epide-
miologic and clinical characteristics of the largest number 
of WNV case-patients to date. In contrast to most previ-
ous studies, our study included all patients identiﬁ  ed with 
WNV illness, regardless of severity (i.e., inpatients and 
outpatients). Among the case-patients identiﬁ   ed in our 
surveillance, univariate analysis identiﬁ  ed older age and 
male sex as signiﬁ  cant independent predictors of develop-
ing neuroinvasive disease, as seen in national surveillance 
data (3). Hypertension and diabetes were also identiﬁ  ed 
as risk factors for developing neuroinvasive disease rather 
than West Nile fever. Notably, the frequency of diabetes 
is higher in patients with West Nile neuroinvasive disease 
than among the general population. The 2001 California 
Health Interview Survey, a population-based, standardized 
telephone health survey of >55,000 households throughout 
California, found that 1,225,000 (11%) persons in Califor-
nia >45 years of age reported ever having received a diag-
nosis of diabetes (4). In contrast, 44% of WNV neuroin-
vasive disease patients >45 years of age in our study had 
diabetes mellitus.
Others have cited diabetes and hypertension as pos-
sible risk factors for progression to West Nile neuroinva-
sive disease or death. In a study of 59 patients hospitalized 
with WNV infection in New York City (5), diabetes was 
an independent risk factor for death (age-adjusted relative 
risk = 5.1; 95% CI 1.5–17.3). A history of hypertension or 
hypertension-inducing drugs was a signiﬁ  cant risk factor 
for encephalitis among 90 hospitalized patients in Hous-
ton (OR = 2.93; 95% CI 0.97–8.89) (6). Additionally, both 
diabetes and hypertension were predictors of severe illness 
in 656 WNV patients reported in Colorado in 2003 (7). 
Most recently, in a review of 221 persons hospitalized with 
WNV infection, West Nile encephalitis was 4 times more 
likely to develop in patients with diabetes (8).
Different mechanisms have been proposed to explain 
how diabetes and hypertension might promote the devel-
opment of WNV neuroinvasive disease. Diabetes and its 
role in impairing immune status may lead to an increase 
in the magnitude and duration of WNV viremia, while hy-
pertension may cause disruption of the blood-brain barrier, 
thereby promoting viral entry into the central nervous sys-
tem (9).
This study had several limitations. Local health depart-
ments collected case history forms for all reported cases, 
but only 58% were complete. Case history forms for the se-
verely ill neuroinvasive patients may have been more thor-
oughly completed than those for West Nile fever patients. 
Because this surveillance was not designed to speciﬁ  cally 
evaluate the contribution of diabetes to WNV disease, the 
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Table 1. Characteristics of WNV cases reported in California, 2005* 
Characteristic WNND, no./total (%)  WNF, no./total (%)  95% Confidence interval  p value† 
Sex, M  188/305 (62)  270/534 (51)  1.18–2.09 <0.01
Age, y 
  <18  12/305 (4)  19/534 (4)  0.53–2.32 0.85
 18–44  73/305  (24)  180/534  (34)  0.45–0.85 <0.01
  45–64  121/305 (40)  240/534 (45)  0.61–1.07 0.15
 65–74  51/305  (17)  61/534  (11)  1.09–2.33 0.03
>75 48/305 (16)  33/534 (6)  1.78–4.53 <0.0001
Symptom 
Fever 254/283 (90)  315/456 (69)  2.54–6.04 <0.0001
Headache 202/262 (77)  387/483 (80)  0.58–1.20 0.33
Rash 54/244 (22)  239/469 (51)  0.19–0.39 <0.0001
Muscle pain/weakness  215/274 (78)  393/485 (81)  0.59–1.23 0.40
Seizures 11/153 (7)  2/313 (0.6)  2.64–55.06 0.001
Altered mental status  148/275 (54)  68/463 (15)  4.77–9.61 <0.0001
*WNV, West Nile virus; WNND, West Nile neuroinvasive disease; WNF, West Nile fever. 
†Fisher exact test, 2-tailed. 
Table 2. Univariate analysis of potential risk factors for developing WNND versus WNF* 
Characteristic WNF, no. (%)  WNND, no. (%)  Odds ratio  95% Confidence interval 
Diabetes 39 (11)  60 (34)  4.15 2.63–6.55
Age >64 y  94 (18)  99 (32)  2.24 1.62–3.11
Hypertension  105 (29)  83  (46)  2.08 1.44–3.01
Male Sex 270 (51)  188 (62)  1.57 1.18–2.09
*WNND, West Nile neuroinvasive disease; WNF, West Nile fever. DISPATCHES
information collected on the case history form was limited. 
However, given the similar ﬁ  ndings of other studies, the 
conclusions from the data are convincing.
In summary, underlying diabetes, as well as older age 
and male sex, appears to be a signiﬁ  cant risk factor for 
development of WNV neuroinvasive disease. Continued 
investigation of the role of diabetes, including the degree 
of severity of diabetic disease, as measured by markers 
such as degree of end-organ damage (e.g., insulin require-
ments, presence of diabetic retinopathy, or end stage renal 
disease), is needed to better identify high-risk patients and 
target prevention messages.
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